Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARQT 
Arcutis Biotherapeutics Inc (ARQT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ARQT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.86
1 Year Target Price $21.86
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 94.4% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.86B USD | Price to earnings Ratio - | 1Y Target Price 21.86 |
Price to earnings Ratio - | 1Y Target Price 21.86 | ||
Volume (30-day avg) 7 | Beta 1.84 | 52 Weeks Range 8.03 - 17.75 | Updated Date 08/28/2025 |
52 Weeks Range 8.03 - 17.75 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.17 | Actual -0.13 |
Profitability
Profit Margin -35.4% | Operating Margin (TTM) -17.93% |
Management Effectiveness
Return on Assets (TTM) -13.46% | Return on Equity (TTM) -57.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1795854470 | Price to Sales(TTM) 7.05 |
Enterprise Value 1795854470 | Price to Sales(TTM) 7.05 | ||
Enterprise Value to Revenue 6.82 | Enterprise Value to EBITDA -2.04 | Shares Outstanding 119905000 | Shares Floating 85575055 |
Shares Outstanding 119905000 | Shares Floating 85575055 | ||
Percent Insiders 1.94 | Percent Institutions 109.93 |
Upturn AI SWOT
Arcutis Biotherapeutics Inc
Company Overview
History and Background
Arcutis Biotherapeutics, Inc. was founded in 2016. It is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company has rapidly advanced its pipeline of novel topical and oral therapies.
Core Business Areas
- Medical Dermatology: Arcutis focuses on developing and commercializing innovative therapies for common dermatological conditions like plaque psoriasis, atopic dermatitis (eczema), seborrheic dermatitis, and vitiligo.
Leadership and Structure
Frank Watanabe serves as the President and CEO. The company has a management team with experience in dermatology and pharmaceutical development. The organizational structure consists of departments focused on research and development, clinical trials, regulatory affairs, commercialization, and finance.
Top Products and Market Share
Key Offerings
- ZORYVE (roflumilast) Topical Cream 0.3%: ZORYVE is a topical PDE4 inhibitor approved for plaque psoriasis, including intertriginous areas, in individuals 12 years and older. While specific market share data is difficult to pinpoint due to the competitive landscape, ZORYVE represents a significant advancement in topical psoriasis treatment. Competitors include topical corticosteroids, vitamin D analogs, and other topical PDE4 inhibitors, with ZORYVE aiming to provide a steroid-free alternative.
- ZORYVE (roflumilast) Topical Foam 0.3%: Zoryve is a topical PDE4 inhibitor approved for seborrheic dermatitis in individuals 9 years and older. Specific market share is being established, but offers a steroid-free treatment option. Competitors include ketoconazole and topical corticosteroids
Market Dynamics
Industry Overview
The dermatology market is characterized by a high prevalence of skin conditions, driving demand for effective treatments. The market is competitive, with numerous pharmaceutical companies developing and commercializing products. Increasing awareness, aging populations, and advancements in drug development are fueling market growth.
Positioning
Arcutis is positioned as an innovative dermatology company focused on developing and commercializing novel, non-steroidal therapies for common skin conditions. Its competitive advantage lies in its roflumilast-based products and its focus on addressing unmet needs in dermatology.
Total Addressable Market (TAM)
The global dermatology market is estimated at over $30 billion. Arcutis is targeting segments such as psoriasis, atopic dermatitis, seborrheic dermatitis, and vitiligo, representing a substantial TAM. Their positioning aims to capture a significant portion through non-steroidal options.
Upturn SWOT Analysis
Strengths
- FDA-approved product (ZORYVE)
- Novel PDE4 inhibitor technology
- Experienced management team
- Strong intellectual property portfolio
- Focus on unmet needs in dermatology
Weaknesses
- Reliance on single product (ZORYVE)
- Limited commercial history
- High R&D expenses
- Market access and reimbursement challenges
Opportunities
- Expansion of ZORYVE indications
- Development of new pipeline products
- Partnerships and collaborations
- Geographic expansion
- Increasing awareness of skin conditions
Threats
- Competition from established dermatology companies
- Generic erosion of existing products
- Regulatory hurdles
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BMY
- LLY
- LEO
- VRX
Competitive Landscape
Arcutis faces competition from established dermatology companies with larger portfolios and marketing resources. Its advantage lies in its novel, steroid-free therapies, but it needs to effectively compete for market share and secure reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to successful commercialization of ZORYVE and pipeline development. Significant recent growth in revenue due to Zoryve.
Future Projections: Future growth depends on expanding ZORYVE market share, launching new products, and achieving positive clinical trial results. Analyst projections are unavailable.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting clinical trials for new indications, and securing reimbursement agreements.
Summary
Arcutis Biotherapeutics is a promising dermatology company with a focus on innovative, non-steroidal therapies. The successful commercialization of ZORYVE is crucial for its growth. The company needs to effectively compete with larger players and manage its cash flow. Its pipeline and expansion into new indications can drive future value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcutis Biotherapeutics Investor Relations
- Company Press Releases
- SEC Filings
- Third-party Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may vary. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcutis Biotherapeutics Inc
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2020-01-31 | President, CEO & Director Mr. Todd Franklin Watanabe M.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 342 | Website https://www.arcutis.com |
Full time employees 342 | Website https://www.arcutis.com | ||
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.